Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1978 Jun;37(6):1026–1032. doi: 10.1038/bjc.1978.149

A Possible Combination of Hypoxic Cell Sensitizer with an Oxic Protector: Implications for Radiotherapy

D Krishnan, D R Singh, U Madhvanath
PMCID: PMC2009649  PMID: 354671

Abstract

This paper discusses the results of experiments using γ-rays and a hypoxic sensitizer metronidazole (MET) and also a well-known protector, mercaptoethylamine (MEA), individually and in combination, on the survival of the yeast S. cerevisiae BZ 34. MET (5mM) gave a hypoxic enhancement ratio (ER) of 1·3. MEA (5mM, 10mM) gave a dose-modifying factor (DMF) of 1·9 and 2·3 respectively for euoxic cells. However, the DMFs for hypoxic cells were 1·0 and 1·1 for 5 and 10mM concentrations of MEA. A combination of 5mM MEA and 5mM MET gave a DMF of 2·0 for euoxic cells and the ER remained at 1·3 for hypoxic cells. The “effective” oxygen enhancement ratios were 2·3 and 1·7 for the control and the sensitizer respectively. In the combination this value was equal to or even slightly less than 1. All DMF, ER and OER values were derived from D0 values of the survival curves. The values based on 10% survival are almost equal to those derived from D0 values. All the survival curves gave the same extrapolation number, showing that the chemicals individually or in combination were truly dose-modifying.

These results indicate that protectors such as MEA could be preferentially protecting euoxic cells, and that combining such “oxic protectors” with a hypoxic sensitizer could result in protecting euoxic cells while the sensitization of hypoxic cells was not much reduced. The implications of our results for radiotherapy are discussed. It appears that the use of nontoxic oxic protectors may be a useful adjuvant in overcoming the hypoxic-cell problem in radiotherapy.

Full text

PDF
1026

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Cooke M. S. Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol Relat Stud Phys Chem Med. 1969 Jul;15(5):457–471. doi: 10.1080/09553006914550741. [DOI] [PubMed] [Google Scholar]
  2. Antoku S. Chemical protection of bacteria and cultured mammalian cells by sulfur-containing compounds. J Radiat Res. 1975 Mar;16(1):28–36. doi: 10.1269/jrr.16.28. [DOI] [PubMed] [Google Scholar]
  3. Antoku S., Gholipour-Khalili K. Effect of oxygen on bacteria and cultured mammalian cells irradiated in the frozen state. Int J Radiat Biol Relat Stud Phys Chem Med. 1977 Aug;32(2):145–152. doi: 10.1080/09553007714550821. [DOI] [PubMed] [Google Scholar]
  4. Asquith J. C., Foster J. L., Willson R. L., Ings R., McFadzean J. A. Metronidazole ("Flagyl"). A radiosensitizer of hypoxic cells. Br J Radiol. 1974 Aug;47(560):474–481. doi: 10.1259/0007-1285-47-560-474. [DOI] [PubMed] [Google Scholar]
  5. BRIDGES B. A. Protection of Pseudomonas sp. against gamma-radiation by dimethyl sulphoxide. Int J Radiat Biol Relat Stud Phys Chem Med. 1962 Apr;5:101–104. doi: 10.1080/09553006214550611. [DOI] [PubMed] [Google Scholar]
  6. COHEN L., COHEN A. Experimental evaluation of systemic medication (cysteamine, menadione, flavonoids and corticoids, modifying reactions to radiotherapy. Br J Radiol. 1959 Jan;32(373):18–21. doi: 10.1259/0007-1285-32-373-18. [DOI] [PubMed] [Google Scholar]
  7. Chapman J. D., Reuvers A. P., Borsa J., Petkau A., McCalla D. R. Nitrofurans as radiosensitizers of hypoxic mammalian cells. Cancer Res. 1972 Dec;32(12):2616–2624. [PubMed] [Google Scholar]
  8. Denekamp J., Michael B. D., Harris S. R. Hypoxic cell radiosensitizers: comparative tests of some electron affinic compounds using epidermal cell survival in vivo. Radiat Res. 1974 Oct;60(1):119–132. [PubMed] [Google Scholar]
  9. Deutsch G., Foster J. L., McFadzean J. A., Parnell M. Human studies with "high dose" metronidazole: a non-toxic radiosensitizer of hypoxic cells. Br J Cancer. 1975 Jan;31(1):75–80. doi: 10.1038/bjc.1975.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Foster J. L., Willson R. L. Radiosensitization of anoxic cells by metronidazole. Br J Radiol. 1973 Mar;46(543):234–235. doi: 10.1259/0007-1285-46-543-234. [DOI] [PubMed] [Google Scholar]
  11. Hall E. J., Roizin-Towle L. Hypoxic sensitizers: radiobiological studies at the cellular level. Radiology. 1975 Nov;117(2):453–457. doi: 10.1148/117.2.453. [DOI] [PubMed] [Google Scholar]
  12. Harris J. W., Phillips T. L. Radiobiolgoical and biochemical studies of thiophosphate radioprotective compounds related to cysteamine. Radiat Res. 1971 May;46(2):362–379. [PubMed] [Google Scholar]
  13. Krishnan D., Singh D. R., Mahajan J. M., Madhvanath U. Absence of sensitization of reversions in yeast by metronidazole. Int J Radiat Biol Relat Stud Phys Chem Med. 1977 Mar;31(3):289–293. doi: 10.1080/09553007714550341. [DOI] [PubMed] [Google Scholar]
  14. Millar B. C., Fielden E. M., Smithen C. E. Polyfunctional radiosensitizers III. Effect of the biradical (Ro-03-303) in combination with other radiosensitizers on the survival of hypoxic V-79 cells. Radiat Res. 1977 Mar;69(3):489–499. [PubMed] [Google Scholar]
  15. Moore B. A., Palcic B., Skarsgard L. D. Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells. Radiat Res. 1976 Sep;67(3):459–473. [PubMed] [Google Scholar]
  16. Phillips T. L. Chemical modification of radiation effects. Cancer. 1977 Feb;39(2 Suppl):987–998. doi: 10.1002/1097-0142(197702)39:2+<987::aid-cncr2820390739>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  17. Pohlit W. Radiation sensitivity and repair capacity dependent on cell concentration? Biophysik. 1973;10(3):33–37. doi: 10.1007/BF01189908. [DOI] [PubMed] [Google Scholar]
  18. Singh D. R., Mahajan J. M., Krishnan D. Effect of dimethyl sulfoxide (DMSO) on radiation-induced heteroallelic reversion in diploid yeast. Mutat Res. 1976 Nov;37(2-3):193–200. doi: 10.1016/0027-5107(76)90033-6. [DOI] [PubMed] [Google Scholar]
  19. Thomlinson R. H., Dische S., Gray A. J., Errington L. M. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours. Clin Radiol. 1976 Apr;27(2):167–174. doi: 10.1016/s0009-9260(76)80139-0. [DOI] [PubMed] [Google Scholar]
  20. Urtasun R. C., Band P., Chapman J. D., Rabin H. R., Wilson A. F., Fryer C. G. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977 Mar;122(3):801–804. doi: 10.1148/122.3.801. [DOI] [PubMed] [Google Scholar]
  21. Urtasun R. C., Chapman J. D., Band P., Rabin H. R., Fryer C. G., Sturmwind J. Phase 1 study of high-dose metronidazole: a specific in vivo and in vitro radiosensitizer of hypoxic cells. Radiology. 1975 Oct;117(1):129–133. doi: 10.1148/117.1.129. [DOI] [PubMed] [Google Scholar]
  22. Utley J. F., Phillips T. L., Kane L. J., Wharam M. D., Wara W. M. Differential radioprotection of euoxic and hypoxic mouse mammary tumors by a thiophosphate compound. Radiology. 1974 Jan;110(1):213–216. doi: 10.1148/110.1.213. [DOI] [PubMed] [Google Scholar]
  23. Yuhas J. M. Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). J Natl Cancer Inst. 1973 Jan;50(1):69–78. doi: 10.1093/jnci/50.1.69. [DOI] [PubMed] [Google Scholar]
  24. Yuhas J. M., Storer J. B. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst. 1969 Feb;42(2):331–335. [PubMed] [Google Scholar]
  25. Yuhas J. M., Yurconic M., Kligerman M. M., West G., Peterson D. F. Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy. Radiat Res. 1977 May;70(2):433–443. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES